Inotiv, Inc. Common Stock (NOTV) Stock Price

NOTVStock

$0.00−57.16%52W

Market Cap—

P/E—

PEG Ratio—

Div yield—

Beta0.34

NOTV Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-105.26%

Price vs S&P 500 (4W)-22.99%

VGM Score52.41

Book Value / Share (Quarterly)$2.21

P/TBV (Annual)29.75x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-2.16%

Cash Flow / Share (Quarterly)$-0.39

Price vs S&P 500 (YTD)-107.02%

Gross Margin (TTM)22.94%

Net Profit Margin (TTM)-17.14%

EPS (TTM)$-2.52

10-Day Avg Trading Volume0.33M

EPS Excl Extra (TTM)$-2.52

Revenue Growth (5Y)53.35%

EPS (Annual)$-2.11

ROI (Annual)-12.61%

Gross Margin (Annual)23.58%

Net Profit Margin (5Y Avg)-20.64%

Cash / Share (Quarterly)$0.44

Revenue Growth QoQ (YoY)-5.37%

ROA (Last FY)-8.90%

Revenue Growth TTM (YoY)5.61%

EBITD / Share (TTM)$0.22

ROE (5Y Avg)-47.25%

Operating Margin (TTM)-9.48%

Cash Flow / Share (Annual)$-0.79

P/B Ratio0.01x

P/B Ratio (Quarterly)0.12x

Net Income / Employee (Annual)$-35,300

EV / Revenue (TTM)0.81x

Net Interest Coverage (TTM)-0.55x

ROA (TTM)-11.72%

EV / EBITDA (TTM)53.61x

EPS Incl Extra (Annual)$-2.11

Current Ratio (Annual)0.35x

Quick Ratio (Quarterly)0.18x

3-Month Avg Trading Volume14.08M

52-Week Price Return-57.16%

Revenue / Employee (TTM)$260,900

Tangible BV / Share (Quarterly)$0.57

P/S Ratio (Annual)0.00x

Asset Turnover (Annual)0.67x

52-Week High$1.49

Operating Margin (5Y Avg)-18.44%

EPS Excl Extra (Annual)$-2.11

CapEx CAGR (5Y)21.79%

Tangible BV CAGR (5Y)11.54%

26-Week Price Return-98.17%

Quick Ratio (Annual)0.23x

13-Week Price Return-97.15%

Total Debt / Equity (Annual)3.00x

Current Ratio (Quarterly)0.27x

Enterprise Value$412.88M

Revenue / Share Growth (5Y)23.29%

Asset Turnover (TTM)0.68x

Book Value / Share Growth (5Y)41.79%

Revenue / Employee (Annual)$263,800

Inventory Turnover (Annual)12.27x

Pretax Margin (Annual)-17.11%

Cash / Share (Annual)$0.63

3-Month Return Std Dev359.30%

Gross Margin (5Y Avg)27.51%

Net Income / Employee (TTM)$-44,700

EBITDA CAGR (5Y)91.57%

ROE (Last FY)-50.45%

Net Interest Coverage (Annual)-0.86x

EPS Basic Excl Extra (Annual)$-2.11

P/FCF (TTM)0.03x

Receivables Turnover (TTM)7.67x

Total Debt / Equity (Quarterly)5.55x

EPS Incl Extra (TTM)$-2.52

Receivables Turnover (Annual)6.76x

ROI (TTM)-16.44%

P/S Ratio (TTM)0.00x

Pretax Margin (5Y Avg)-24.60%

Revenue / Share (Annual)$15.81

Tangible BV / Share (Annual)$0.57

Price vs S&P 500 (52W)-62.16%

Year-to-Date Return-98.03%

5-Day Price Return-37.64%

EPS Normalized (Annual)$-2.11

ROA (5Y Avg)-13.33%

Net Profit Margin (Annual)-13.38%

Month-to-Date Return7.77%

Cash Flow / Share (TTM)$-10.97

EBITD / Share (Annual)$0.77

Operating Margin (Annual)-6.02%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)1.10x

ROI (5Y Avg)-18.25%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.52

P/TBV (Quarterly)29.75x

P/B Ratio (Annual)0.37x

Inventory Turnover (TTM)11.40x

Pretax Margin (TTM)-20.84%

Book Value / Share (Annual)$3.96

Price vs S&P 500 (13W)-103.34%

Beta0.34x

P/FCF (Annual)1.03x

Revenue / Share (TTM)$14.64

ROE (TTM)-74.67%

52-Week Low$0.01

vGradeB

gGradeB

mGradeF

vgmGradeC

NOTV Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q1 2026	May 11, 2026	-$0.64	-$0.94	-48.03%(-$0.30)
Q4 2025	Feb 9, 2026	-$0.64	-$0.83	-29.69%(-$0.19)
Q3 2025	Dec 3, 2025	-$0.08	-$0.21	-157.50%(-$0.13)
Q2 2025	Aug 6, 2025	-$0.15	-$0.48	-217.33%(-$0.33)

NOTV Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.13

Industry Peers — R&D — Physical Sciences(17)

Symbol	Value Score	Growth Score	Momentum Score	P/E Ratio (Annual)	ROE (TTM)	Revenue Growth (5Y)	Indicated Dividend Yield (Annual)	Price
NOTVInotiv, Inc. Common Stock	B	B	F	—	-74.7%	53.4%	—	$0.00
IQVIQVIA Holdings Inc.	D	C	A	32.3x	21.9%	7.5%	—	$266.90
INCYIncyte Genomics Inc	C	B	B	17.8x	29.6%	14.0%	—	$113.07
MEDPMedpace Holdings, Inc. Common Stock	F	B	B	38.3x	110.2%	22.3%	—	$618.47
CRLCharles River Laboratories International, Inc.	F	D	A	—	-7.7%	6.5%	—	$300.15
ICLRIcon Plc	C	C	B	57.3x	0.8%	24.1%	—	$170.18
ABSIAbsci Corporation Common Stock	F	F	B	—	-59.2%	-10.1%	—	$8.25
OABIOmniAb, Inc. Common Stock	F	B	A	—	-16.6%	-4.3%	—	$4.59
NRCNRC Health Common Stock	D	D	B	38.4x	48.5%	0.6%	1.2%	$20.15
MXCTMaxCyte, Inc. Common Stock	C	D	B	—	-21.0%	4.8%	—	$1.30
IBACIB Acquisition Corp. Common Stock	—	D	C	15.9x	-3.7%	—	—	$10.86
ONMDOneMedNet Corp Class A Common Stock	D	A	D	—	-6.8%	—	—	$4.51
BIAFbioAffinity Technologies, Inc. Common Stock	A	C	F	—	-257.3%	—	—	$3.73
ISPCiSpecimen Inc. Common Stock	—	F	F	—	-524.4%	-25.1%	—	$0.92
BIAFWbioAffinity Technologies, Inc. Warrant	—	—	C	—	—	—	—	$0.32
IBACRIB Acquisition Corp. Right	—	D	C	15.9x	-3.7%	—	—	$0.11
OABIWOmniAb, Inc. Warrant	—	—	B	—	—	—	—	$0.24
ONMDWOneMedNet Corp Warrant	—	—	C	—	—	—	—	$0.03

About Inotiv, Inc. Common Stock

Inotiv provides nonclinical and analytical drug development services to pharmaceutical, chemical, and medical device companies. Operating through two segments—Discovery and Safety Assessment and Research Models and Services—the company supports small molecule and biologic drug discovery while supplying specialized research models for disease-specific applications. The Research Models and Services segment generates the majority of revenue.